Verdezyne Sells One of Its Technologies to DuPont Industrial Biosciences

Verdezyne, an industrial biotechnology company based in Carlsbad, Calif., has sold its proprietary xylose isomerase technology to DuPont Industrial Biosciences for an undisclosed amount. Current investors in Verdezyne include BP Alternative Energy Ventures, DSM Venturing B.V., OVP Venture Partners and Monitor Ventures.

PRESS RELEASE:

Verdezyne, Inc., a privately-held industrial biotechnology company focused on producing renewable chemicals, announced the sale of its proprietary xylose isomerase technology, enabling the metabolism of 5-carbon sugars, to DuPont Industrial Biosciences, a world leader in science and innovation.

Under the terms of the sale, DuPont has purchased rights to Verdezyne’s patented xylose isomerase technology, covered by U.S. Patent Nos. 8,114,974 and 8,093,037, for use in the rapidly-commercializing biofuels and biochemical fields. This technology allows the fast and complete utilization of biomass-sourced C5 sugars in production of various products of choice. This technological breakthrough was highlighted in a recent Journal of Industrial Microbiology & Biotechnology article published August 2012.

“Verdezyne’s xylose isomerase technology has been shown to have superior performance compared to alternatives for converting 5-carbon sugar to fuels and chemicals,” said E. William Radany, Ph.D., president and CEO of Verdezyne. “We are pleased that a company of DuPont’s stature recognizes the value of our proprietary technology.”

“Biomass bioprocessing is opening up unique market opportunities across a wide range of DuPont businesses and the Verdezyne technology is a natural fit for the company’s cellulosic portfolio,” said John P. Ranieri, vice president, DuPont Industrial Biosciences. “The addition of this leading xylose isomerase technology further strengthens DuPont’s leadership in biomass derived sugar conversion to biofuels and biochemicals.”

About Verdezyne

Verdezyne is an industrial biotechnology company using proven and proprietary metabolic pathway engineering tools to develop unique yeast strains for cost-effective production of bio-based chemicals. Current investors in Verdezyne include BP Alternative Energy Ventures, DSM Venturing B.V., OVP Venture Partners and Monitor Ventures. For more information, visit www.verdezyne.com .

About DuPont Industrial Biosciences

DuPont Industrial Biosciences works with customers across a wide range of industries to improve products and make processes more sustainable. Through a unique combination of capabilities in agriculture, biotechnology, chemistry and material science, coupled with the power of 2,000 talented individuals worldwide, this DuPont business focuses on providing biobased solutions to meet the needs of a growing population while protecting our environment.

Related Posts

Leave a Reply

PEHUB Community

Join the 12502 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Create your free online surveys with SurveyMonkey , the world's leading questionnaire tool.

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget